{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T04:39:42Z","timestamp":1695530382755},"reference-count":55,"publisher":"Bentham Science Publishers Ltd.","issue":"17","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2020,6,4]]},"abstract":"<jats:sec><jats:title \/><jats:p>Autoantibiodies against aminoacyl-tRNA synthetases are found in patients suffering from a wide range of autoimmune and inflammatory disorders. Recent data indicate that these antibodies are directed against splice-variants of synthetase genes, the so-called catalytic nulls. Latter molecules have cytokine-like functions and are involved in the regulation of the activation of lymphocytes, monocytes and granulocytes. The potential role of anti-synthetase antibodies as a diagnostic tool and a target for therapeutic interventions is discussed.<\/jats:p><\/jats:sec>","DOI":"10.2174\/0929867326666191128141215","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T15:59:40Z","timestamp":1574956780000},"page":"2863-2871","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Haywain: Anti-synthetase Antibodies in Patients with Inflammatory Diseases: Targeting Monocytes or Neutrophils?"],"prefix":"10.2174","volume":"27","author":[{"given":"Bob","family":"Meek","sequence":"first","affiliation":[{"name":"Laboratory for Medical Microbiology and Immunology, St Antonius Hospital Nieuwegein, Middelburg, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ger T.","family":"Rijkers","sequence":"additional","affiliation":[{"name":"Laboratory for Medical Microbiology and Immunology, St Antonius Hospital Nieuwegein, Middelburg, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.autrev.2015.12.002","volume":"15","author":"Fritzler M.J.","year":"2016","unstructured":"Fritzler M.J.; Choosing wisely: Review and commentary on anti-nuclear antibody (ANA) testing. Autoimmun Rev 2016,15(3),272-280","journal-title":"Autoimmun Rev"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1568-9972(03)00006-5","volume":"2","author":"Cooper G.S.","year":"2003","unstructured":"Cooper G.S.; Stroehla B.C.; The epidemiology of autoimmune diseases. Autoimmun Rev 2003,2(3),119-125","journal-title":"Autoimmun Rev"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"iii3","DOI":"10.1093\/rheumatology\/kel282","volume":"45","author":"Gaubitz M.","year":"2006","unstructured":"Gaubitz M.; Epidemiology of connective tissue disorders. Rheumatology (Oxford) 2006,45(Suppl. 3),iii3-iii4","journal-title":"Rheumatology (Oxford)"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3389\/fimmu.2015.00412","volume":"6","author":"Chan E.K.","year":"2015","unstructured":"Chan E.K.; Damoiseaux J.; Carballo O.G.; Conrad K.; de Melo Cruvinel W.; Francescantonio P.L.; Fritzler M.J.; Garcia-De La Torre I.; Herold M.; Mimori T.; Satoh M.; von M\u00fchlen C.A.; Andrade L.E.; Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014-2015. Front Immunol 2015,6,412","journal-title":"Front Immunol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.autrev.2015.10.007","volume":"15","author":"Selmi C.","year":"2016","unstructured":"Selmi C.; Ceribelli A.; Generali E.; Scir\u00e8 C.A.; Alborghetti F.; Colloredo G.; Porrati L.; Achenza M.I.; De Santis M.; Cavaciocchi F.; Massarotti M.; Isailovic N.; Paleari V.; Invernizzi P.; Matthias T.; Zucchi A.; Meroni P.L.; Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years. Autoimmun Rev 2016,15(2),162-166","journal-title":"Autoimmun Rev"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ymeth.2016.11.014","volume":"113","author":"Fang P.","year":"2017","unstructured":"Fang P.; Guo M.; Structural characterization of human aminoacyl-tRNA synthetases for translational and nontranslational functions. Methods 2017,113,83-90","journal-title":"Methods"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/art.1780230802","volume":"23","author":"Nishikai M.","year":"1980","unstructured":"Nishikai M.; Reichlin M.; Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum 1980,23(8),881-888","journal-title":"Arthritis Rheum"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1084\/jem.160.2.420","volume":"160","author":"Mathews M.B.","year":"1984","unstructured":"Mathews M.B.; Reichlin M.; Hughes G.R.; Bernstein R.M.; Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody. J Exp Med 1984,160(2),420-434","journal-title":"J Exp Med"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.4049\/jimmunol.144.5.1737","volume":"144","author":"Targoff I.N.","year":"1990","unstructured":"Targoff I.N.; Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis. J Immunol 1990,144(5),1737-1743","journal-title":"J Immunol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","volume":"52","author":"Satoh M.","year":"2017","unstructured":"Satoh M.; Tanaka S.; Ceribelli A.; Calise S.J.; Chan E.K.; A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 2017,52(1),1-19","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","volume":"13","author":"Lega J.C.","year":"2014","unstructured":"Lega J.C.; Fabien N.; Reynaud Q.; Durieu I.; Durupt S.; Dutertre M.; Cordier J.F.; Cottin V.; The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev 2014,13(9),883-891","journal-title":"Autoimmun Rev"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s11926-013-0335-1","volume":"15","author":"Ghirardello A.","year":"2013","unstructured":"Ghirardello A.; Bassi N.; Palma L.; Borella E.; Domeneghetti M.; Punzi L.; Doria A.; Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep 2013,15(6),335","journal-title":"Curr Rheumatol Rep"},{"key":"ref=13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060442","volume":"8","author":"Hamaguchi Y.","year":"2013","unstructured":"Hamaguchi Y.; Fujimoto M.; Matsushita T.; Kaji K.; Komura K.; Hasegawa M.; Kodera M.; Muroi E.; Fujikawa K.; Seishima M.; Yamada H.; Yamada R.; Sato S.; Takehara K.; Kuwana M.; Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One 2013,8(4)","journal-title":"PLoS One"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"Bohan A.","year":"1975","unstructured":"Bohan A.; Peter J.B.; Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975,292(7),344-347","journal-title":"N Engl J Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"Bohan A.","year":"1975","unstructured":"Bohan A.; Peter J.B.; Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975,292(8),403-407","journal-title":"N Engl J Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/mus.24566","volume":"51","author":"Findlay A.R.","year":"2015","unstructured":"Findlay A.R.; Goyal N.A.; Mozaffar T.; An overview of polymyositis and dermatomyositis. Muscle Nerve 2015,51(5),638-656","journal-title":"Muscle Nerve"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.rmed.2016.10.019","volume":"121","author":"Hozumi H.","year":"2016","unstructured":"Hozumi H.; Fujisawa T.; Nakashima R.; Johkoh T.; Sumikawa H.; Murakami A.; Enomoto N.; Inui N.; Nakamura Y.; Hosono Y.; Imura Y.; Mimori T.; Suda T.; Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease. Respir Med 2016,121,91-99","journal-title":"Respir Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3949\/ccjm.80a.12171","volume":"80","author":"Chatterjee S.","year":"2013","unstructured":"Chatterjee S.; Prayson R.; Farver C.; Antisynthetase syndrome: not just an inflammatory myopathy. Cleve Clin J Med 2013,80(10),655-666","journal-title":"Cleve Clin J Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.rmed.2017.10.020","volume":"132","author":"Yura H.","year":"2017","unstructured":"Yura H.; Sakamoto N.; Satoh M.; Ishimoto H.; Hanaka T.; Ito C.; Hasegawa T.; Tanaka S.; Miyamura T.; Nakashima S.; Hara A.; Kakugawa T.; Oda K.; Kido T.; Obase Y.; Ishimatsu Y.; Yatera K.; Kawakami A.; Mukae H.; Clinical characteristics of patients with anti-aminoacyl-tRNA synthetase antibody positive idiopathic interstitial pneumonia. Respir Med 2017,132,189-194","journal-title":"Respir Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","volume":"56","author":"Pinal-Fernandez I.","year":"2017","unstructured":"Pinal-Fernandez I.; Casal-Dominguez M.; Huapaya J.A.; Albayda J.; Paik J.J.; Johnson C.; Silhan L.; Christopher-Stine L.; Mammen A.L.; Danoff S.K.; A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology (Oxford) 2017,56(6),999-1007","journal-title":"Rheumatology (Oxford)"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3899\/jrheum.131251","volume":"41","author":"Saketkoo L.A.","year":"2014","unstructured":"Saketkoo L.A.; Mittoo S.; Frankel S.; LeSage D.; Sarver C.; Phillips K.; Strand V.; Matteson E.L.; Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases. J Rheumatol 2014,41(4),792-798","journal-title":"J Rheumatol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ejrad.2014.11.026","volume":"84","author":"Debray M.P.","year":"2015","unstructured":"Debray M.P.; Borie R.; Revel M.P.; Naccache J.M.; Khalil A.; Toper C.; Israel-Biet D.; Estellat C.; Brillet P.Y.; Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings. Eur J Radiol 2015,84(3),516-523","journal-title":"Eur J Radiol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/MCP.0000000000000298","volume":"22","author":"Strek M.E.","year":"2016","unstructured":"Strek M.E.; Costabel U.; Interstitial pneumonia with autoimmune features: a critical appraisal of the new definition. Curr Opin Pulm Med 2016,22(5),442-449","journal-title":"Curr Opin Pulm Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1183\/13993003.00150-2015","volume":"46","author":"Fischer A.","year":"2015","unstructured":"Fischer A.; Antoniou K.M.; Brown K.K.; Cadranel J.; Corte T.J.; du Bois R.M.; Lee J.S.; Leslie K.O.; Lynch D.A.; Matteson E.L.; Mosca M.; Noth I.; Richeldi L.; Strek M.E.; Swigris J.J.; Wells A.U.; West S.G.; Collard H.R.; Cottin V.; An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 2015,46(4),976-987","journal-title":"Eur Respir J"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0140-6736(12)61079-4","volume":"380","author":"Fischer A.","year":"2012","unstructured":"Fischer A.; du Bois R.; Interstitial lung disease in connective tissue disorders. Lancet 2012,380(9842),689-698","journal-title":"Lancet"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1183\/09031936.00060107","volume":"31","author":"Tzelepis G.E.","year":"2008","unstructured":"Tzelepis G.E.; Toya S.P.; Moutsopoulos H.M.; Occult connective tissue diseases mimicking idiopathic interstitial pneumonias. Eur Respir J 2008,31(1),11-20","journal-title":"Eur Respir J"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.rmed.2009.02.009","volume":"103","author":"Mittoo S.","year":"2009","unstructured":"Mittoo S.; Gelber A.C.; Christopher-Stine L.; Horton M.R.; Lechtzin N.; Danoff S.K.; Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease. Respir Med 2009,103(8),1152-1158","journal-title":"Respir Med"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/ar3097","volume":"12","author":"Castelino F.V.","year":"2010","unstructured":"Castelino F.V.; Varga J.; Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. Arthritis Res Ther 2010,12(4),213","journal-title":"Arthritis Res Ther"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1126\/science.1252943","volume":"345","author":"Lo W.S.","year":"2014","unstructured":"Lo W.S.; Gardiner E.; Xu Z.; Lau C.F.; Wang F.; Zhou J.J.; Mendlein J.D.; Nangle L.A.; Chiang K.P.; Yang X.L.; Au K.F.; Wong W.H.; Guo M.; Zhang M.; Schimmel P.; Human tRNA synthetase catalytic nulls with diverse functions. Science 2014,345(6194),328-332","journal-title":"Science"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"19269","DOI":"10.1074\/jbc.C114.571026","volume":"289","author":"Zhou J.J.","year":"2014","unstructured":"Zhou J.J.; Wang F.; Xu Z.; Lo W.S.; Lau C.F.; Chiang K.P.; Nangle L.A.; Ashlock M.A.; Mendlein J.D.; Yang X.L.; Zhang M.; Schimmel P.; Secreted histidyl-tRNA synthetase splice variants elaborate major epitopes for autoantibodies in inflammatory myositis. J Biol Chem 2014,289(28),19269-19275","journal-title":"J Biol Chem"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nrm.2017.77","volume":"19","author":"Schimmel P.","year":"2018","unstructured":"Schimmel P.; The emerging complexity of the tRNA world: mammalian tRNAs beyond protein synthesis. Nat Rev Mol Cell Biol 2018,19(1),45-58","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1126\/science.284.5411.147","volume":"284","author":"Wakasugi K.","year":"1999","unstructured":"Wakasugi K.; Schimmel P.; Two distinct cytokines released from a human aminoacyl-tRNA synthetase. Science 1999,284(5411),147-151","journal-title":"Science"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20020186","volume":"196","author":"Howard O.M.","year":"2002","unstructured":"Howard O.M.; Dong H.F.; Yang D.; Raben N.; Nagaraju K.; Rosen A.; Casciola-Rosen L.; H\u00e4rtlein M.; Kron M.; Yang D.; Yiadom K.; Dwivedi S.; Plotz P.H.; Oppenheim J.J.; Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med 2002,196(6),781-791","journal-title":"J Exp Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"11043","DOI":"10.1073\/pnas.0802862105","volume":"105","author":"Park S.G.","year":"2008","unstructured":"Park S.G.; Schimmel P.; Kim S.; Aminoacyl tRNA synthetases and their connections to disease. Proc Natl Acad Sci USA 2008,105(32),11043-11049","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/nature14028","volume":"519","author":"Sajish M.","year":"2015","unstructured":"Sajish M.; Schimmel P.; A human tRNA synthetase is a potent PARP1-activating effector target for resveratrol. Nature 2015,519(7543),370-373","journal-title":"Nature"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nrneurol.2011.63","volume":"7","author":"Mammen A.L.","year":"2011","unstructured":"Mammen A.L.; Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol 2011,7(6),343-354","journal-title":"Nat Rev Neurol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/304177a0","volume":"304","author":"Mathews M.B.","year":"1983","unstructured":"Mathews M.B.; Bernstein R.M.; Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature 1983,304(5922),177-179","journal-title":"Nature"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1096\/fasebj.9.12.7672516","volume":"9","author":"Martin A.","year":"1995","unstructured":"Martin A.; Shulman M.J.; Tsui F.W.; Epitope studies indicate that histidyl-tRNA synthetase is a stimulating antigen in idiopathic myositis. FASEB J 1995,9(12),1226-1233","journal-title":"FASEB J"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"24277","DOI":"10.1016\/S0021-9258(19)51078-X","volume":"269","author":"Raben N.","year":"1994","unstructured":"Raben N.; Nichols R.; Dohlman J.; McPhie P.; Sridhar V.; Hyde C.; Leff R.; Plotz P.; A motif in human histidyl-tRNA synthetase which is shared among several aminoacyl-tRNA synthetases is a coiled-coil that is essential for enzymatic activity and contains the major autoantigenic epitope. J Biol Chem 1994,269(39),24277-24283","journal-title":"J Biol Chem"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1172\/JCI114461","volume":"85","author":"Miller F.W.","year":"1990","unstructured":"Miller F.W.; Twitty S.A.; Biswas T.; Plotz P.H.; Origin and regulation of a disease-specific autoantibody response. Antigenic epitopes, spectrotype stability, and isotype restriction of anti-Jo-1 autoantibodies. J Clin Invest 1990,85(2),468-475","journal-title":"J Clin Invest"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.str.2012.08.001","volume":"20","author":"Xu Z.","year":"2012","unstructured":"Xu Z.; Wei Z.; Zhou J.J.; Ye F.; Lo W.S.; Wang F.; Lau C.F.; Wu J.; Nangle L.A.; Chiang K.P.; Yang X.L.; Zhang M.; Schimmel P.; Internally deleted human tRNA synthetase suggests evolutionary pressure for repurposing. Structure 2012,20(9),1470-1477","journal-title":"Structure"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3389\/fimmu.2016.00311","volume":"7","author":"Porto B.N.","year":"2016","unstructured":"Porto B.N.; Stein R.T.; Neutrophil extracellular traps in pulmonary diseases: too much of a good thing? Front Immunol 2016,7,311","journal-title":"Front Immunol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/cei.12319","volume":"177","author":"Zhang S.","year":"2014","unstructured":"Zhang S.; Shu X.; Tian X.; Chen F.; Lu X.; Wang G.; Enhanced formation and impaired degradation of neutrophil extracellular traps in dermatomyositis and polymyositis: a potential contributor to interstitial lung disease complications. Clin Exp Immunol 2014,177(1),134-141","journal-title":"Clin Exp Immunol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11926-015-0532-1","volume":"17","author":"Ascherman D.P.","year":"2015","unstructured":"Ascherman D.P.; Role of Jo-1 in the immunopathogenesis of the anti-synthetase syndrome. Curr Rheumatol Rep 2015,17(9),56","journal-title":"Curr Rheumatol Rep"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1128\/CMR.00112-16","volume":"30","author":"Williamson D.A.","year":"2017","unstructured":"Williamson D.A.; Carter G.P.; Howden B.P.; Current and emerging topical antibacterials and antiseptics: agents, action, and resistance patterns. Clin Microbiol Rev 2017,30(3),827-860","journal-title":"Clin Microbiol Rev"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/emmm.201100626","volume":"5","author":"Yao P.","year":"2013","unstructured":"Yao P.; Fox P.L.; Aminoacyl-tRNA synthetases in medicine and disease. EMBO Mol Med 2013,5(3),332-343","journal-title":"EMBO Mol Med"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/0897190016660487","volume":"30","author":"Saunders J.","year":"2017","unstructured":"Saunders J.; Maki K.; Koski R.; Nybo S.E.; Tavaborole, Efinaconazole, and Luliconazole: Three new antimycotic agents for the treatment of dermatophytic fungi. J Pharm Pract 2017,30(6),621-630","journal-title":"J Pharm Pract"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1189\/jlb.3RU0417-148RR","volume":"102","author":"Luo Y.","year":"2017","unstructured":"Luo Y.; Xie X.; Luo D.; Wang Y.; Gao Y.; The role of halofuginone in fibrosis: more to be explored? J Leukoc Biol 2017,102(6),1333-1345","journal-title":"J Leukoc Biol"},{"key":"ref=49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186587","volume":"12","author":"Shibata A.","year":"2017","unstructured":"Shibata A.; Kuno M.; Adachi R.; Sato Y.; Hattori H.; Matsuda A.; Okuzono Y.; Igaki K.; Tominari Y.; Takagi T.; Yabuki M.; Okaniwa M.; Discovery and pharmacological characterization of a new class of prolyl-tRNA synthetase inhibitor for anti-fibrosis therapy. PLoS One 2017,12(10)","journal-title":"PLoS One"},{"key":"ref=50","first-page":"A7068","volume":"195","author":"Nangle L.A.","year":"2017","unstructured":"Nangle L.A.; Tong Y.; Crampton S.P.; Adams R.A.; Chiang K.P.; Mertsching E.; Taylor K.; Ogilvie K.M.; McKew J.C.; Ashlock M.A.; Schimmel P.; The resokine pathway is implicated in the pathology of interstitial lung disease. Am J Respir Crit Care Med 2017,195,A7068","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=51","first-page":"A6428","volume":"195","author":"Ogilvie K.M.","year":"2017","unstructured":"Ogilvie K.M.; Do M.T.; Chiang K.P.; Adams R.A.; Crampton S.P.; Nangle L.A.; Cubitt A.B.; McKew J.C.; Ashlock M.A.; Mendlein J.D.; Resokine modulates immune cell infiltration into the lung and provides therapeutic activity in a bleomycin-induced lung fibrosis model. Am J Respir Crit Care Med 2017,195,A6428","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=52","year":"2019","unstructured":"Evaluation of the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of intravenous ATYR1923 in healthy volunteers. Australian New Zealand Clinical trials registry Available at: (Accessed Date: November 2, 2019).2019","journal-title":"Australian New Zealand Clinical trials registry"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/qjmed\/hcx235","volume":"111","author":"McElvaney O.J.","year":"2018","unstructured":"McElvaney O.J.; Horan D.; Franciosi A.N.; Gunaratnam C.; McElvaney N.G.; Pulmonary alveolar proteinosis. QJM 2018,111(3),185-186","journal-title":"QJM"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2217\/bmm-2017-0362","volume":"12","author":"Nishimura M.","year":"2018","unstructured":"Nishimura M.; Yamaguchi E.; Takahashi A.; Asai N.; Katsuda E.; Ohta T.; Ohtsuka Y.; Kosaka K.; Matsubara A.; Tanaka H.; Yokoe N.; Kubo A.; Konno S.; Baba K.; Clinical significance of serum anti-GM-CSF autoantibody levels in autoimmune pulmonary alveolar proteinosis. Biomarkers Med 2018,12(2),151-159","journal-title":"Biomarkers Med"},{"key":"ref=55","unstructured":"The haywain. Museo del Prado. Available at: (Accessed Date : October 2019.)."}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/177038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T12:41:43Z","timestamp":1695472903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/177038\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,4]]},"references-count":55,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2020,6,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867326666191128141215","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-03-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}